Is Ozempic Putting An End To Bariatric Surgery? | Dr. Christine Ren-Fielding
A long interview with a bariatric surgeon on weight biology and surgery, with about 20 minutes on how Ozempic and other GLP-1 drugs compare with it.
With Dr. Christine Ren-Fielding
Key moments
Tap a moment to play the video from there.
- 1:06Set point theory explainedRen-Fielding says the body evolved to store calories and defends a higher weight once gained, which makes calorie restriction feel like starvation.
- 11:24Calories in, calories outBoth agree energy balance holds, but she argues processed carbohydrates and glucose make weight regain easier after weight loss.
- 23:05What bariatric surgery doesShe defines weight loss surgery and describes sleeve gastrectomy and gastric bypass, including their effects on hunger hormones.
- 30:10Success rates and regainShe quotes 30 to 40% body weight loss kept off for decades for some patients, about 20% on average at 10 years, and says obesity needs long-term monitoring.
- 54:23Ozempic versus surgeryShe discusses the drop in surgical numbers, why she welcomes GLP-1 drugs, and why they may not be enough for people with a BMI over 40.
- 1:06:42Are GLP-1 drugs lifelong?Doctor Mike asks why obesity specialists rarely get patients off the drugs. Ren-Fielding says they work only while taken and that weight returns after stopping.
- 1:10:28Medicalizing a societal problemThey discuss whether drugs treat a problem that should be solved through food policy, and why sugar taxes and food reform are hard to pass.
- 1:15:18Food addiction and muscle lossShe calls sugar addiction more common than food addiction in general, and shares concern about muscle loss and losing more than 10 pounds a month.
- 1:18:05How patients are triagedShe explains that, following insurance rules, a BMI of 35 without other conditions leads to medication and lifestyle, while heart disease or insulin use leads toward surgery.
- 1:22:30Combining drugs and surgeryShe says starting GLP-1 drugs during the months of preparation for surgery makes sense for some patients, and that the best sequence is still being studied.
What the video says
This is a 93 minute interview on Doctor Mike's channel with Dr. Christine Ren-Fielding, introduced as chief of bariatric surgery at NYU Langone Health. Most of it covers weight biology, bariatric surgery, insurance and public health. The peptide content is her view of Ozempic and similar GLP-1 medications, which the two discuss mostly as a drug class rather than by active ingredient.
Before reaching the drugs, Ren-Fielding lays out her framework. She describes set point theory, saying the body defends a higher weight once it has been gained. She says diet and exercise alone rarely produce a lasting loss of 100 pounds. She explains the sleeve gastrectomy and gastric bypass, and says surgery works by reducing hunger and cravings and making the stomach smaller, not by changing a person's emotional relationship with food. She says patients lose 30 to 40% of body weight and keep it off for decades, but not everyone, and that the average at 10 years is about 20% of body weight. She puts patient satisfaction above 95%.
On GLP-1 drugs, she says surgeons she has spoken to have seen about a 20% drop in bariatric volume, and that she welcomes the shift because the drugs have opened up a conversation about treating obesity. She credits them with steadier blood sugar and quieter food noise. She says that for people with a BMI over 40 they will not give the long-term loss needed, citing losses of 10%, 20%, maybe 30% of body weight. She believes the drugs must be lifelong for people with severe obesity, since she has seen weight return after stopping, and she notes tolerance, cost and access as limits.
She favors combination therapy, for example starting a GLP-1 while a patient prepares for surgery, and says how best to sequence the two is still being studied. Both speakers voice concern about muscle loss with fast weight loss. The episode also covers BMI criteria, insurance hurdles, a reality TV show about severe obesity, and ultra-processed food.
On each compound
Semaglutide54:52
Ren-Fielding discusses Ozempic and related GLP-1 medications as a class, calling them reliably effective and saying they steady blood sugar and reduce food noise. She says they will not deliver enough long-term loss for people with a BMI over 40, and that she expects them to be lifelong for people with severe obesity.
See how your DNA reads Semaglutide“I think this is reality and it's a wonderful reality”
What this video doesn’t settle
- The discussion is one surgeon's clinical experience, and the figures on weight loss, regain and satisfaction are quoted without citing the underlying studies.
- The video does not establish how best to sequence or combine GLP-1 drugs and surgery, and Ren-Fielding says that research is still under way.
- The drugs are discussed as a class, with no comparison of specific products, doses or side-effect rates.
Questions this video answers
Will Ozempic replace bariatric surgery?
Ren-Fielding says it may eventually, but she does not expect that soon. She cites cost, access, tolerance to the drugs and patient preference as reasons surgery will remain an option.
Do you have to stay on Ozempic or GLP-1 drugs for life?
Ren-Fielding says they work for appetite control only while taken, and that people she has seen who stopped injectables started gaining weight. She thinks this applies most to people over 300 pounds, and less to someone wanting to lose 10 or 20 pounds.
Why does she say GLP-1 drugs may not be enough for severe obesity?
She says these drugs may give 10%, 20%, maybe 30% of body weight. She gives the example of a 600 pound patient who would still weigh about 480 pounds, and says combination therapy with surgery may be needed.
What does Ren-Fielding say about muscle loss on GLP-1 drugs?
She says she is concerned, especially with rapid weight loss, because muscle loss can drive weight regain. She says that in her field losing more than 10 pounds a month suggests substantial muscle loss, and she wonders how a drug could spare muscle without activity.
Should someone with a BMI over 35 consider surgery as well as medication?
She says it depends on health status. With no other medical problems she would discuss medication, diet and activity, but with conditions such as heart disease or insulin-treated diabetes she would plan for surgery.
Video by Doctor Mike on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
